Takeda宣布其用于治疗原发性免疫缺陷病（PID）的TAK-881关键性Ⅱ/Ⅲ期临床试验取得积极顶线结果
businesswire.com
⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in